<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethacrynic acid: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethacrynic acid: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ethacrynic acid: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9429" href="/d/html/9429.html" rel="external">see "Ethacrynic acid: Drug information"</a> and <a class="drug drug_patient" data-topicid="12021" href="/d/html/12021.html" rel="external">see "Ethacrynic acid: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F167963"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Edecrin;</li>
<li>Sodium Edecrin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866805"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Edecrin;</li>
<li>Sodium Edecrin [DSC];</li>
<li>VPI-Ethacrynate Sodium</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058511"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Diuretic, Loop</span></li></ul></div>
<div class="block don drugH1Div" id="F53462444"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis): Note:</b> Ethacrynic acid is a potent diuretic and should be used for clinical conditions refractory to other diuretics, or requiring rapid onset in diuretic response. Very limited data available: IV: 1 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2741861','lexi-content-ref-6726531']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2741861','lexi-content-ref-6726531'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F167984"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose equivalency for adult patients with normal renal function (approximate): Bumetanide 1 mg = furosemide 40 mg = torsemide 20 mg = ethacrynic acid 50 mg</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis): </b>
<b>Note:</b> Ethacrynic acid is a potent diuretic and should be used for clinical conditions refractory to other diuretics, or requiring rapid onset in diuretic response.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Infants (limited data available), Children, and Adolescents: Initial: 1 mg/kg/dose once daily; maximum initial dose should generally not exceed 25 to 50 mg/dose based on experience in adult patients; increase at intervals of 2 to 3 days to a maximum of 3 mg/kg/<b>day</b> in divided doses 1 to 3 times daily not to exceed a maximum daily dose: 400 mg/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV: 0.5 to 1 mg/kg/dose every 8 to 24 hours; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-Park.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Usual reported initial rate: 0.1 mg/kg/hour, titrate to effect; maximum reported infusion rate: 0.5 mg/kg/hour, although in trials, most patients responded to a lower dose. Dosing based on a prospective study of 36 pediatric post-operative cardiac surgery patients (mean age: 135 ± 181 days; mean weight: 4.2 ± 3.1 kg) which reported a mean effective dose of 0.22 ± 0.13 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25563826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25563826'])">Ref</a></span>); a pilot retrospective report of 9 patients reported a mean initial dose 0.13 ± 0.07 mg/kg/hour and a mean maximum rate of 0.17 ± 0.08 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24782692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24782692'])">Ref</a></span>). <b>Note:</b> Monitor serum electrolytes closely; in trials, hypokalemia and metabolic alkalosis was frequently observed.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109556"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; contraindicated in patients with anuria. Based on experience with other loop diuretics (ie, furosemide) in adults, very high doses may be necessary to initiate diuretic effect.</p></div>
<div class="block dohp drugH1Div" id="F51109557"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with severe cirrhosis of the liver; with other loop diuretics (ie, furosemide), diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis has been observed; monitor effects, particularly with high doses.</p></div>
<div class="block doa drugH1Div" id="F167967"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9429" href="/d/html/9429.html" rel="external">see "Ethacrynic acid: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Loop diuretic approximate oral dose equivalency for patients with normal renal function: Ethacrynic acid 50 mg = bumetanide 1 mg = torsemide 10 to 20 mg = furosemide 40 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-8074594','lexi-content-ref-21366472','lexi-content-ref-22676934','lexi-content-ref-7781259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-8074594','lexi-content-ref-21366472','lexi-content-ref-22676934','lexi-content-ref-7781259'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64a84569-d387-4bc2-8369-8004ca9fc0a4">Edema or volume overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or volume overload (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients who develop a hypersensitivity reaction to sulfonamide-based loop diuretics (eg, furosemide, bumetanide, torsemide). Ototoxicity is more common when administered at high doses compared with other loop diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19142155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19142155'])">Ref</a></span>). When used as a replacement for another loop diuretic, refer to the equivalencies above.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Naive to loop diuretics:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 25 to 50 mg once daily; increase dose by 25 to 50 mg/day based on response and tolerability; usual effective dose: 50 to 200 mg/day in 1 to 2 divided doses; for severe, refractory edema, may administer up to 400 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8074594','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8074594','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 50 mg or 0.5 to 1 mg/kg/dose (maximum single dose: 100 mg); usually one dose is sufficient; if needed, a repeat dose can be administered 12 hours later; doses up to 200 mg/day in 2 divided doses for 2 to 5 days have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14632366','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14632366','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991927"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Contraindicated in patients with anuria.</p></div>
<div class="block doha drugH1Div" id="F50989182"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F167931"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, anorexia, diarrhea, dysphagia, gastrointestinal hemorrhage, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site irritation, infusion-site pain</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Apprehension, chills, confusion, fatigue, headache, malaise, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (temporary or permanent), tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hyperuricemia (reversible)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Gout</p></div>
<div class="block coi drugH1Div" id="F167947"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ethacrynic acid or any component of the formulation; anuria; history of severe watery diarrhea caused by this product; infants</p></div>
<div class="block war drugH1Div" id="F167928"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid/electrolyte loss: Loop diuretics are potent diuretics; excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration. In contrast to thiazide diuretics, a loop diuretic can also lower serum calcium concentrations. Electrolyte disturbances can predispose a patient to serious cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Rarely occurs. Ethacrynic acid has no cross-reactivity to sulfonamides or sulfonylureas (Wall 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: Rapid IV administration, renal impairment, excessive doses, and concurrent use of other ototoxins is associated with ototoxicity; has been associated with a higher incidence of ototoxicity than other loop diuretics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Dehydration: Avoid diuretics in the immediate postoperative period after bariatric surgery; electrolyte disturbances and dehydration may occur. Diuretics may be resumed, if indicated, once oral fluid intake goals are met (Ziegler 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with cirrhosis; initiate ethacrynic acid therapy with conservative dosing and close monitoring of electrolytes; avoid sudden changes in fluid and electrolyte balance and acid/base status, which may lead to hepatic encephalopathy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: If administered in the morning prior to surgery, ethacrynic acid may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings and precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diuretic resistance: For some patients, despite high doses of loop diuretic, an adequate diuretic response cannot be attained. Diuretic resistance may be overcome by IV rather than oral administration or the use of two diuretics together (eg, a loop diuretic in combination with a thiazide diuretic). When such combinations are used, serum electrolytes need to be monitored even more closely (ACC [Hollenberg 2019]).</p></div>
<div class="block foc drugH1Div" id="F167939"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as ethacrynate sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sodium Edecrin: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as ethacrynate sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Edecrin: 25 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block geq drugH1Div" id="F167924"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F167949"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ethacrynate Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $4,560.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Sodium Edecrin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $6,017.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Edecrin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $29.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ethacrynic Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.70 - $24.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866806"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as ethacrynate sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sodium Edecrin: 50 mg ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Edecrin: 25 mg [contains corn starch]</p></div>
<div class="block exp drugH1Div" id="F167945"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 1 mg/mL oral suspension may be made with ethacrynic acid powder. Dissolve 120 mg ethacrynic acid powder in a small amount of 10% alcohol. Add a small amount of 50% sorbitol solution and stir. Adjust pH to 7 with 0.1N sodium hydroxide solution. Add sufficient quantity of 50% sorbitol solution to make a final volume of 120 mL. Add methylparaben 6 mg and propylparaben 2.4 mg as preservatives. Stable for 220 days at room temperature.</p>
<div class="reference">Das Gupta V, Gibbs CW Jr, and Ghanekar AG, "Stability of Pediatric Liquid Dosage Forms of Ethacrynic Acid, Indomethacin, Methyldopate Hydrochloride, Prednisone and Spironolactone," <i>Am J Hosp Pharm</i>, 1978, 35(11):1382-5.<span class="pubmed-id">568384</span></div>
<div class="reference">
<i>Handbook on Extemporaneous Formulations</i>, Bethesda, MD: American Society of Hospital Pharmacists, 1987.</div>
</div>
<div class="block admp drugH1Div" id="F52612757"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or milk</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: May be infused without further dilution over a period of several minutes or infused slowly through the tubing of a running infusion; if a second dose is needed, it is recommended to use a new injection site to avoid possible thrombophlebitis. Should <b>not</b> be administered IM or SubQ due to local pain and irritation.</p></div>
<div class="block adm drugH1Div" id="F167943"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use only; do <b>not</b> administer SUBQ or IM due to local pain and irritation. Administer slowly through the tubing of a running infusion or by direct IV injection over ~5 to 20 minutes; rapid administration increases the risk of ototoxicity due to the high concentrations achieved in a short period of time. If a second or repeat doses are needed, rotate the injection site to avoid possible thrombophlebitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5655196','lexi-content-ref-19142159','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5655196','lexi-content-ref-19142159','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer after a meal.</p></div>
<div class="block sts drugH1Div" id="F25211318"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Discard unused reconstituted injection solution after 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53566799"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Short-term management of hospitalized patients with congenital heart disease or nephrotic syndrome (FDA approved in children, adolescents, and adults); management of edema associated with congestive heart failure, hepatic cirrhosis, or renal disease (FDA approved in adults); short-term management of ascites due to malignancy, idiopathic edema, and lymphedema (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Indicated when a rapid onset of diuresis is desired (eg, in acute pulmonary edema or when gastrointestinal absorption is impaired or oral medication is not feasible) (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F168004"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Edecrin may be confused with Eulexin, Ecotrin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]). <b>Note:</b> Updates for the American Geriatrics Society 2023 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults are in process.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299289"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F167933"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amikacin Liposome (Oral Inhalation): Loop Diuretics may enhance the nephrotoxic effect of Amikacin Liposome (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Amikacin Liposome (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Loop Diuretics may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Loop Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: Loop Diuretics may enhance the hypotensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Loop Diuretics may enhance the hypotensive effect of Arsenic Trioxide. Loop Diuretics may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: Loop Diuretics may enhance the QTc-prolonging effect of Bilastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: May enhance the hypotensive effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefaloridine [Cephaloridine]: Loop Diuretics may enhance the nephrotoxic effect of Cefaloridine [Cephaloridine]. Loop Diuretics may increase the serum concentration of Cefaloridine [Cephaloridine]. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefazedone: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefotiam: Loop Diuretics may enhance the nephrotoxic effect of Cefotiam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpirome: Loop Diuretics may enhance the nephrotoxic effect of Cefpirome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceftizoxime: Loop Diuretics may enhance the nephrotoxic effect of Ceftizoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Loop Diuretics may enhance the nephrotoxic effect of Cephalothin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephradine: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk for hyperuricemia and gout may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: May enhance the hyponatremic effect of Loop Diuretics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Loop Diuretics may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.  Management: Monitor serum potassium and magnesium more closely when dofetilide is combined with loop diuretics. Electrolyte replacements will likely be required to maintain potassium and magnesium serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Empagliflozin: May enhance the hypotensive effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: Loop Diuretics may increase the serum concentration of Foscarnet.  Management: When diuretics are indicated during foscarnet treatment, thiazides are recommended over loop diuretics. If patients receive loop diuretics during foscarnet treatment, monitor closely for evidence of foscarnet toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the ototoxic effect of Ethacrynic Acid.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iodinated Contrast Agents: Loop Diuretics may enhance the nephrotoxic effect of Iodinated Contrast Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipragliflozin: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Loop Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Loop Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Ophthalmic): Loop Diuretics may enhance the nephrotoxic effect of Netilmicin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Loop Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobramycin (Oral Inhalation): Loop Diuretics may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Loop Diuretics may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Ethacrynic Acid may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Xipamide: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoledronic Acid: Loop Diuretics may enhance the hypocalcemic effect of Zoledronic Acid. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F167951"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May cause potassium loss; potassium supplement or dietary changes may be required.</p></div>
<div class="block pri drugH1Div" id="F167950"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. </p></div>
<div class="block mopp drugH1Div" id="F53566787"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes including calcium and magnesium (baseline and frequently during therapy); blood pressure; renal function parameters (baseline and frequently during therapy); fluid balance (bodyweight; neonatal and young pediatric patients may require more frequent monitoring than older patients); hearing (with high doses or extended duration), blood glucose</p></div>
<div class="block pha drugH1Div" id="F167927"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and distal renal tubule, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium</p></div>
<div class="block phk drugH1Div" id="F167946"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Diuresis: Oral: ~30 minutes; IV: 5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Oral: 2 hours; IV: 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: 12 hours; IV: 2 to 4 hours (Molnar 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~100% (Molnar 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (35% to 40%) to active cysteine conjugate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces and urine (30% to 60% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038612"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Edecrin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Edecrin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Edecril | Edecrin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Edecrin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hydromedin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Edecrin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Uregyt | Uregyt egis</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Reomax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Edecril</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Edecrin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hydromedin | Uregyt</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Edecrin | Ethacrynic acid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Edecrina</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Edecrin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Uregyt</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14632366">
<a name="14632366"></a>Alisky JM, Tuttle TF. Ethacrynic acid can be effective for refractory congestive heart failure and ascites. <i>South Med J</i>. 2003;96(11):1148-1150. doi:10.1097/01.SMJ.0000082004.40613.D7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/14632366/pubmed" id="14632366" target="_blank">14632366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099505">
<a name="22099505"></a>Brater DC. Update in diuretic therapy: clinical pharmacology. <i>Semin Nephrol</i>. 2011;31(6):483-494. doi:10.1016/j.semnephrol.2011.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/22099505/pubmed" id="22099505" target="_blank">22099505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.1">
<a name="Brater.1"></a>Brater DC, Ellison DH. Loop diuretics: dosing and major side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2741861">
<a name="2741861"></a>Chemtob S, Doray JL, Laudignon N, Papageorgiou A, Varma DR, Aranda JV. Alternating sequential dosing with furosemide and ethacrynic acid in drug tolerance in the newborn. <i>Am J Dis Child</i>. 1989;143(7):850-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/2741861/pubmed" id="2741861" target="_blank">2741861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8074594">
<a name="8074594"></a>Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. <i>Arch Intern Med.</i> 1994;154(17):1905-1914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/8074594/pubmed" id="8074594" target="_blank">8074594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cowley.1">
<a name="Cowley.1"></a>Cowley AJ and Elkeles RS, “Diabetes and Therapy With Potent Diuretics,” <i>Lancet</i>, 1978, 1(8056):154.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Edecrin.1">
<a name="Edecrin.1"></a>Edecrin tablets and IV Sodium Edecrin [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals America LLC; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21366472">
<a name="21366472"></a>Felker GM, Lee KL, Bull DA, et al; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. <i>N Engl J Med</i>. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/21366472/pubmed" id="21366472" target="_blank">21366472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22676934">
<a name="22676934"></a>Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. <i>J Am Coll Cardiol</i>. 2012;59(24):2145-2153. doi:10.1016/j.jacc.2011.10.910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/22676934/pubmed" id="22676934" target="_blank">22676934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gomolin.1">
<a name="Gomolin.1"></a>Gomolin IH and Garschick E, “Ethacrynic Acid-Induced Deafness Accompanied by Nystagmus,” <i>N Engl J Med</i>, 1980, 303(12):702.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526538">
<a name="31526538"></a>Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: A report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/31526538/pubmed" id="31526538" target="_blank">31526538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lant.1">
<a name="Lant.1"></a>Lant A, “Diuretics: Clinical Pharmacology and Therapeutic Use,” <i>Drugs</i>, 1985, 29(1):57-87.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5655196">
<a name="5655196"></a>Lesch M, Caranasos GJ, Mulholland JH. Controlled study comparing ethacrynic acid to mercaptomerin in the treatment of acute pulmonary edema. <i>N Engl J Med</i>. 1968;279(3):115-122. doi:10.1056/NEJM196807182790301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/5655196/pubmed" id="5655196" target="_blank">5655196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24782692">
<a name="24782692"></a>Miller JL, Schaefer J, Tam M, Harrison DL, Johnson PN. Ethacrynic Acid continuous infusions in critically ill pediatric patients. <i>J Pediatr Pharmacol Ther</i>. 2014;19(1):49-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/24782692/pubmed" id="24782692" target="_blank">24782692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142159">
<a name="19142159"></a>Molnar J, Somberg JC. The clinical pharmacology of ethacrynic acid. <i>Am J Ther</i>. 2009;16(1):86-92. doi:10.1097/MJT.0b013e318195e460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/19142159/pubmed" id="19142159" target="_blank">19142159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25563826">
<a name="25563826"></a>Ricci Z, Haiberger R, Pezzella C, Garisto C, Favia I, Cogo P. Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial. <i>Crit Care</i>. 2015;19:2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/25563826/pubmed" id="25563826" target="_blank">25563826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6726531">
<a name="6726531"></a>Scalais E, Papageorgiou A, Aranda JV. Effects of ethacrynic acid in the newborn infant. <i>J Pediatr</i>. 1984;104(6):947-950.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/6726531/pubmed" id="6726531" target="_blank">6726531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142155">
<a name="19142155"></a>Somberg JC, Molnar J. The management of acute heart failure and diuretic therapy. <i>Am J Ther</i>. 2009;16(1):93-97. doi:10.1097/MJT.0b013e3181966c06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/19142155/pubmed" id="19142155" target="_blank">19142155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5663735">
<a name="5663735"></a>Sparrow AW, Friedberg DZ, Nadas AS. The use of ethacrynic acid in infants and children with congestive heart failure. <i>Pediatrics</i>. 1968;42(2):291-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/5663735/pubmed" id="5663735" target="_blank">5663735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7781259">
<a name="7781259"></a>Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. <i>Clin Pharmacol Ther</i>. 1995;57(6):601-609. doi: 10.1016/0009-9236(95)90222-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/7781259/pubmed" id="7781259" target="_blank">7781259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523926">
<a name="12523926"></a>Wall GC, Bigner D, Craig S. Ethacrynic acid and the sulfa-sensitive patient. <i>Arch Intern Med</i>. 2003;163(1):116-117. doi:10.1001/archinte.163.1.116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/12523926/pubmed" id="12523926" target="_blank">12523926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20152742">
<a name="20152742"></a>Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. <i>Diabetes Metab</i>. 2009;35(6, pt 2):544-557. doi: 10.1016/S1262-3636(09)73464-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/20152742/pubmed" id="20152742" target="_blank">20152742</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12901 Version 303.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
